Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma. At present, the treatment of new diagnosed AITL has limited efficacy and a high recurrence rate. The study seeks to explore the possibility of improving the efficacy of immunotherapy and chemotherapy and epigenetically regulated drugs.

NCT Number	NCT07168317
Lead Sponsor	The Affiliated Hospital of Xuzhou Medical University
Conditions	New Diagnosed Angioimmunoblastic T-Cell Lymphoma
Enrollment	40 participants
Start Date	2025-08-01
Primary Completion	2028-08-01 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-11